University of Toronto

Funded By:

Canadian Breast Cancer Foundation (Ontario Chapter)

Status:

Complete

Summary:

Women with a BRCA1 or BRCA2 mutation have a very high lifetime risk of developing breast cancer, and later, new breast cancers in the same or opposite breast.  Our previous research demonstrated that various treatments reduce these risks of new breast cancers.  However, it is currently unclear what effect cancer treatments have on survival in women with BRCA-associated breast cancer.  Typically, women with BRCA-associated breast cancers receive similar treatment to women with sporadic breast cancer.  However, women with BRCA-associated breast cancers have a significantly increased risk of developing ipsilateral or contralateral breast cancers after the first breast cancer diagnosis.  This study will provide information on the effectiveness of various cancer treatments on long-term survival in women with BRCA-associated breast cancers. 

Publications:

Foulkes, WD, Metcalfe, K, Hanna, W, Lynch HT, Ghadirian, P, Tung, N, Olopade, O, Weber, B, McLennan, J, Olivotto, O, Sun, P, Chappuis, PO, Begin, LR, Brunet, JS,  Narod, SA.  (2003). Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinomaCancer, 98(8), pp. 1569-1577. 

Foulkes, WD, Metcalfe, K, Sun, P., Hanna, W, Lynch HT, Ghadirian, P, Tung, N, Olopade, O, Weber, B, McLennan, J, Olivotto, O, Begin, LR, & Narod, SA.  (2004).  Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.  Clinical Cancer Research,10(6), pp. 2029-2034. 

Metcalfe, K, Lynch, H, Ghadirian, P, Tung, N, Olivotto, I, Foulkes, W, Warner, E, Olopade, O, Eisen, A, Weber, B, McLennan, J, Sun, P, & Narod, S. (2004).  The risk of contralateral breast cancer in BRCA1 and BRCA2 CarriersJournal of Clinical Oncology, 22(12), pp.2328-35. 

Metcalfe, K, Lynch, H, Ghadirian, P, Tung, N, Olivotto, I, Foulkes, W, Warner, E, Olopade, O, Eisen, A, Weber, B, McLennan, J, Sun, P, & Narod, S. (2005).  The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 CarriersGynecologic Oncology96(2005), pp.222-226

Metcalfe, K, Foulkes, W, Lynch, H, Ghadirian, P, Tung, N, Olivotto, I, Warner, E, Olopade, O, Eisen, A, Weber, B, McLennan, J, Sun, P, & Narod, S. (2005). The Effect of Prior Bilateral Salpingo-Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Hereditary Factors in Clinical Cancer3(2), pp. 53-57. 

Metcalfe, K, Lynch, H, Ghadirian, P, Tung, N, Olivotto, I, Foulkes, W, Warner, E, Olopade, O, Eisen, A, Weber, B, McLennan, J, Sun, P, & Narod, S. (2010).  Risk of ipsilateral breast cancer  in women with a BRCA1 or BRCA2 Mutation.  Breast Cancer Research and Treatment 127(1):287-96).

Metcalfe, K, Lynch, H, Ghadirian, P, Tung, N, Olivotto, I, Foulkes, W, Warner, E, Olopade, O, Eisen, A, Weber, B, McLennan, J, Sun, P, & Narod, S. (2011). Contralateral breast cancer risks in women with a BRCA1 or BRCA2 Mutation.  British Journal of Cancer. 104(9):1384-92